吉利德创新药物Seladelpar也在本届进博会上迎来中国“首秀”。该药物已于2024年8月获得美国食品药品监督管理局（FDA）加速审批，为原发性胆汁性胆管炎患者的二线治疗带来了全新选择。作为一种慢性自身免疫性肝内胆汁淤积性疾病，原发性胆汁性胆管炎（ ...

你是否曾好奇，那些困扰人类已久的疾病，是否真的有被治愈的希望？在第七届中国国际进口博览会上，全球领先的生物制药公司吉利德科学为我们带来了令人振奋的消息。他们不仅展示了针对罕见病原发性胆汁性胆管炎（PBC）的新药Seladelpar，还分享了长效HIV预防疗法Lenacapavir的重大进展。 想象一下，如果有一种药物能够有效控制甚至逆转一种罕见但致命的肝脏疾病，那将意味着什么？原发性胆汁性胆管炎就 ...

医师报讯 ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

11月5日，第七届中国国际进口博览会开幕首日，全球领先的生物制药企业吉利德科学展台正式揭幕。围绕“创造一个更健康的世界”这一主题，吉利德在500平方米展台上全方位展现公司在病毒学、肿瘤学、真菌学三大核心领域的革新疗法及研发进展，集中展示通过创新合作提升健康公平可及的主要成果，再次彰显其深耕中国市场、服务国内患者、加强共赢合作的坚定决心。

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

(GILD) Wednesday said it has signed royalty-free licensing agreements with six pharmaceutical manufacturers to manufacture and supply generic versions of the company's HIV drug lenacapavir ...

US pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries – a key step towards making it available across the region, where ...

Kisii — The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting into the body and making copies of itself.

In this open-label, active-controlled study, virologically suppressed adults on Biktarvy were randomly allocated in a 1:1 ratio to receive either oral islatravir 2 mg and lenacapavir 300 mg once a ...